Skip to main content

Table 3 Subgroup analyses of the individual trials and combined data set (one-stage IPDMM)

From: Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis

   FOCUS AFFINITY EFFECTS Combined
   Fluoxetine
(n=)
Placebo
(n=)
COR
(95% CI)
p-value
Fluoxetine
(n=)
Placebo
(n=)
COR
(95% CI)
p-value
Fluoxetine
(n=)
Placebo
(n=)
COR
(95% CI)
p-value
Fluoxetine
(n=)
Placebo
(n=)
COR
(95% CI)
p-value
Probability of being alive and independent at 6 months using SSV 0 to ≤0∙15             
0.15-1.00             
Delay from onset to randomisation 2-8 days             
9-15 days             
Motor deficit No             
Yes             
Aphasia No             
Yes             
Stroke type Haemorrhagic             
Ischaemic             
Age group ≤70 years old             
>70 years old             
Who gave consent Proxy             
Patient             
Inability to assess mood No             
Yes             
Baseline depression No             
Yes             
Country UK             
Vietnam             
New Zealand             
Australia             
Sweden             
Ethnicity Asian             
Black             
Chinese             
White             
Other             
Trial FOCUS             
AFFINITY             
EFFECTS             
  1. Abbreviations: CI confidence interval, COR common odds ratio, SSV six simple variables
\